Octagen

Octagen Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment

Octagen Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of hemophilia and genetic disorders of the clotting process. It develops two variations of recombinant B domain deleted porcine factor VIII to avoid inactivation by flying below the radar screen of the immune system. The company was founded in 1997 and is based in Penn Valley, Pennsylvania. As of July 17, 2008, Octagen Corporation operates as a subsidiary of Ipsen S.A.